Clinical Trial

An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to valuate the sensitivity and specificity of different blood biomarkers for monitoring and assessing Aβ-PET-confirmed mitigation of amyloid pathology by lencanumab treatment in subjects treated with lencanumab.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2025-07-01 -> 2027-12-31 2026-08-01
minor Completion pushed: 2025-12-31 -> 2027-12-31 2026-08-01
Trial Details
NCT Number NCT07153848
Lead Sponsor First Affiliated Hospital of Zhejiang University
Conditions Alzheimer Disease
Enrollment 400 participants
Start Date 2024-07-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-31